Related Experiment Video
Updated: Feb 10, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Pharmacogenetics in heart failure trials
Mona Fiuzat1, Michael R Bristow
1Duke University Medical Center, 2400 Pratt Street, Durham, NC 27710, USA. mona.fiuzat@duke.edu
Abstract:
There is ongoing research into potential pharmacogenetic targets in heart failure. Several challenges exist despite the potential benefits, and questions remain on the level of evidence needed to support product approval or labeling. High annual mortality, high morbidity, and heterogeneity of response to treatment underscore the need for predictability of response in this patient population. Although prime time testing and application of pharmacogenetics is not currently being used in heart failure, we believe this treatment approach is not too distant. The data are supportive, and further research is warranted to strengthen the approach.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Pathophysiology of Heart Failure
Heart Failure Drugs: Diuretics

